ASCO GU 2024: Study shows positive results for patients with muscle-invasive urothelial carcinoma
Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have…
Browsing: ASCO
ASCO GU 2024: Subcutaneous nivolumab as effective as IV for renal cell carcinoma with much faster treatment time
Subcutaneous injection of the immunotherapy nivolumab is non-inferior to intravenous delivery and dramatically reduces treatment…
ASCO GI 2024: Dual immunotherapy treatment improves progression-free survival in certain patients with advanced colorectal cancer
The dual immunotherapy combination of nivolumab and ipilimumab reduced the risk of disease progression or…
ASCO GI 2024: New study adds to ambiguity of role of post-operative ctDNA to guide treatment in patients with low-risk, stage IIA colon cancer
The role of ctDNA, or liquid biopsy, as a predictive tool to guide and monitor…
ASCO GI 2024: New immunotherapy combinations for patients with oesophageal cancer
Results from a new phase III study found that combining PD-L1 and TIGIT inhibitors plus…
ASCO GI 2024: Adding immunotherapy-based combination to TACE improves progression-free survival in patients with most common liver cancer
The addition of durvalumab and bevacizumab to TACE significantly improved progression-free survival in patients with…
ASCO GU 2024: Combination of cabozantinib and atezolizumab offers hope for patients with type of advanced prostate cancer with poor prognosis
Patients with metastatic castration-resistant prostate cancer (mCRPC) with extrapelvic nodal or visceral metastasis who were…
ASCO updates Geriatric Oncology Guidelines
The American Society of Clinical Oncology (ASCO) has issued updated guidelines for geriatric oncology, outlining…
ASCO 2023: Personalised vaccines may revolutionise cancer treatment
Researchers from Edith Cowan University (ECU) are leading ground-breaking global trials which could save lives…
ASCO 2023: New drug combination twice as effective for some ovarian cancer patients as next best treatment
A targeted drug combination for patients with a type of ovarian cancer could be nearly twice as…